1-5 of 5
Matthew C. Riddle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Matthew C. Riddle, MD, David A. D’Alessio, MD, Stephen A. Brunton, MD, Curtis L. Triplitt, PharmD, CDCES
Journal: Diabetes
Diabetes 2022;71(8):1601–1602
https://doi.org/10.2337/db22-en08
Published: 21 August 2022
View articletitled, A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement
Open the PDF for A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement in another window
Meeting Abstracts

864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED

SILVIO E. INZUCCHI, DEEPAK L. BHATT, BERTRAM PITT, MICHAEL SZAREK, CHRISTOPHER P. CANNON, JULIA B. LEWIS, MATTHEW C. RIDDLE, MIKHAIL N. KOSIBOROD, DAVID CHERNEY, JAMIE P. DWYER, BENJAMIN M. SCIRICA, CLIFFORD J. BAILEY, PHILLIP L. BANKS, RAFAEL DIAZ, KAUSIK K. RAY, JACOB A. UDELL, RENATO D. LOPES, LAWRENCE A. LEITER, PHILIPPE G. STEG, SCORED INVESTIGATORS
Journal: Diabetes
Diabetes 2022;71(Supplement_1):864-P
https://doi.org/10.2337/db22-864-P
Published: 01 June 2022
View articletitled, 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED
Meeting Abstracts

32-OR: The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial

JOHN J.V. MCMURRAY, MASON W. FREEMAN, JOE MASSARO, SCOTT SOLOMON, PAUL LOCK, MATTHEW C. RIDDLE, ELDRIN LEWIS, YUAN-DI C. HALVORSEN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):32-OR
https://doi.org/10.2337/db20-32-OR
Published: 01 June 2020
View articletitled, 32-OR: The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
Meeting Abstracts

924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND

HELEN M. COLHOUN, CLINTON HASENOUR, MATTHEW C. RIDDLE, KELLEY BRANCH, MANIGE KONIG, CHARLES ATISSO, MARK LAKSHMANAN, REEMA MODY, HERTZEL C. GERSTEIN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):924-P
https://doi.org/10.2337/db20-924-P
Published: 01 June 2020
View articletitled, 924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND
Meeting Abstracts

1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event

MAGNUS O. WIJKMAN, BRIAN CLAGGETT, RAFAEL DIAZ, HERTZEL C. GERSTEIN, LARS KOBER, ELDRIN LEWIS, ALDO P. MAGGIONI, EMIL WOLSK, DAVID AGUILAR, RHONDA BENTLEY-LEWIS, JOHN J. MCMURRAY, JEFFREY L. PROBSTFIELD, MATTHEW C. RIDDLE, JEAN-CLAUDE TARDIF, SCOTT SOLOMON, MARC A. PFEFFER
Journal: Diabetes
Diabetes 2020;69(Supplement_1):1421-P
https://doi.org/10.2337/db20-1421-P
Published: 01 June 2020
View articletitled, 1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event